Found: 25
Select item for more details and to access through your institution.
Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 6, p. 2287, doi. 10.1002/alz.12877
- By:
- Publication type:
- Article
Baseline participant characteristics of GRADUATION: a study to evaluate once‐weekly subcutaneous administration of gantenerumab.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.061781
- By:
- Publication type:
- Article
Linking amyloid to clinical outcome: A quantitative semi‐mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer's disease and the effects of anti‐amyloid treatment.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 3, p. 1, doi. 10.1002/alz.067069
- By:
- Publication type:
- Article
Graduation study design: Evaluation of once‐weekly subcutaneous administration of gantenerumab on brain amyloid load.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.052060
- By:
- Publication type:
- Article
Characterization of amyloid‐related imaging abnormality in the DIAN‐TU‐001 trial.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.056393
- By:
- Publication type:
- Article
Why does ARIA‐E appear bright? A quantitative model linking brain tissue composition and T<sub>2</sub> FLAIR hyperintensities: Neuroimaging / evaluating treatments.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.046115
- By:
- Publication type:
- Article
DT‐01‐02: CONTINUED LARGE AMYLOID PET REDUCTIONS AT 36 MONTHS IN THE GANTENERUMAB OPEN‐LABEL EXTENSION STUDIES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1484, doi. 10.1016/j.jalz.2019.08.005
- By:
- Publication type:
- Article
O1‐09‐02: THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P240, doi. 10.1016/j.jalz.2018.06.2379
- By:
- Publication type:
- Article
O1‐09‐03: 24‐MONTH AMYLOID PET RESULTS OF THE GANTENERUMAB HIGH‐DOSE OPEN LABEL EXTENSION STUDIES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P240, doi. 10.1016/j.jalz.2018.06.2380
- By:
- Publication type:
- Article
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
- Published in:
- Alzheimer's Research & Therapy, 2019, v. 11, n. 1, p. 1, doi. 10.1186/s13195-019-0559-z
- By:
- Publication type:
- Article
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
- Published in:
- Alzheimer's Research & Therapy, 2017, v. 9, p. 1, doi. 10.1186/s13195-017-0318-y
- By:
- Publication type:
- Article
[<sup>11</sup>C]-RO5013853: a New PET Radioligand for the Glycine Transporter TYPE 1.
- Published in:
- Neuropsychopharmacology, 2014, v. 39, n. 9, p. 2272, doi. 10.1038/npp.2014.52
- By:
- Publication type:
- Article
Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
- Published in:
- Annals of Neurology, 2022, v. 92, n. 5, p. 729, doi. 10.1002/ana.26511
- By:
- Publication type:
- Article
Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 4, p. 857, doi. 10.1002/cpt.2535
- By:
- Publication type:
- Article
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 1, p. 62, doi. 10.1002/psp4.12876
- By:
- Publication type:
- Article
Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 8, p. 673, doi. 10.1007/s40262-013-0061-x
- By:
- Publication type:
- Article
Effect of Saquinavir-Ritonavir on Cytochrome P450 3A4 Activity in Healthy Volunteers Using Midazolam as a Probe.
- Published in:
- Pharmacotherapy, 2009, v. 29, n. 10, p. 1175, doi. 10.1592/phco.29.10.1175
- By:
- Publication type:
- Article
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2022, v. 49, n. 5, p. 557, doi. 10.1007/s10928-022-09821-z
- By:
- Publication type:
- Article
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, v. 8, n. 1, p. 1, doi. 10.1002/trc2.12306
- By:
- Publication type:
- Article
Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
- Published in:
- Psychopharmacology, 2016, v. 233, n. 13, p. 2429, doi. 10.1007/s00213-016-4317-7
- By:
- Publication type:
- Article
LanV, a Bifunctional Enzyme: Aromatase and Ketoreductase during Landomycin A Biosynthesis.
- Published in:
- ChemBioChem, 2005, v. 6, n. 12, p. 2312, doi. 10.1002/cbic.200500205
- By:
- Publication type:
- Article
Generation of Novel Landomycins M and O through Targeted Gene Disruption.
- Published in:
- ChemBioChem, 2005, v. 6, n. 4, p. 675, doi. 10.1002/cbic.200400316
- By:
- Publication type:
- Article